- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00580359
S-1 vs Capecitabine in the Elderly and/or Poor Performance Status Patients With Recurrent or Metastatic Gastric Cancer
A Randomized Phase II Study of S-1 Versus Capecitabine as First-Line Chemotherapy in the Elderly and/or Poor Performance Status Patients With Recurrent or Metastatic Gastric Cancer
This study is an open-label, single-center, and randomized phase II study designed to evaluate each efficacy and safety of S-1 and capecitabine in the elderly and/or poor performance status patients with recurrent or metastatic gastric cancer. The randomization will be stratified by age (70-85 years versus 65 years and < 70 years) and performance status, which is dependent on age group; in 70-85 years, ECOG performance status 0-1 versus 2 and in ³65 years and <70 years, ECOG performance status 2 versus 3.
- S-1 40mg/m2 orally twice daily on days 1 (evening) - 15 (morning)
- Capecitabine 1250mg/m2 orally twice daily on days 1 (evening) - 15 (morning) Treatment will be administered every 3 weeks and will be continued in the absence of disease progression or unacceptable toxicity.
Study Overview
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Sook Ryun Park, M.D.
- Phone Number: +82-31-920-1609
- Email: sukryun73@ncc.re.kr
Study Contact Backup
- Name: So Yun Park, MS
- Phone Number: +82-31-920-2309
- Email: tomongmong@naver.com
Study Locations
-
-
Gyeonggi
-
Goyang, Gyeonggi, Korea, Republic of
- Recruiting
- National Cancer Center Korea
-
Contact:
- Sook Ryun Park, M.D
- Phone Number: +82-31-920-1609
- Email: sukryun73@ncc.re.kr
-
Contact:
- So Yun Park, MS
- Phone Number: +82-31-920-2307
- Email: tomongmong@naver.com
-
Sub-Investigator:
- Noe Kyeong Kim, M.D
-
Sub-Investigator:
- Young Iee Park, M.D
-
Sub-Investigator:
- Byung-Ho Nam, M.D
-
Sub-Investigator:
- Hye Suk Han, M.D
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologically or cytologically confirmed gastric adenocarcinoma with recurrent or metastatic disease
- Age of 70-85 years with Eastern Cooperative Oncology Group (ECOG) performance status 0-2 or age ≥65 and <70 with ECOG performance status ≥ 2
Measurable disease as defined by Response Evaluation Criteria In Solid Tumors (RECIST) Measurable lesions:
Lesions that can be accurately measured in at least one dimension by any of the following:
- Computed tomography (CT) of abdomen, pelvis or thorax, if the longest diameter to be recorded is at least 10 mm with spiral CT
- Chest x-ray, if the lung lesion to be recorded is clearly defined and surrounded by aerated lung and the diameter to be recorded is at least 20 mm- Physical examination, if the clinically detected lesions are superficial (e.g., skin nodule and palpable lymph nodes) and at least 10 mm
- No prior chemotherapy for recurrent and/or metastatic disease (prior adjuvant/neoadjuvant chemotherapy is allowed at least 6 months has relapsed between completion of adjuvant/neoadjuvant therapy and enrolment into the therapy; prior S-1 or capecitabine is not allowed)
Adequate major organ function including the following:
Hematopoietic function:
- absolute neutrophil count (ANC)≥1,500/mm3,
- Platelet ≥ 100,000/mm3,
Hepatic function:
- serum bilirubin =< 1.5 x upper limit of normal (ULN),
- AST/ALT levels =< 2.5 x ULN ( 5 x ULN if liver metastases are present)
Renal function:
- serum creatinine =< 1.5 x ULN
- Patients should sign a written informed consent before study entry
Exclusion Criteria:
- Lack of physical integrity of the upper gastrointestinal tract or malabsorption syndrome (e.g. patients with partial or total gastrectomy can enter the study, but not those with a jejunostomy probe), or inability to take oral medication
- Patients with active (significant or uncontrolled) gastrointestinal bleeding
Inadequate cardiovascular function:
- New York Heart Association class III or IV heart disease
- Unstable angina or myocardial infarction within the past 6 months
- History of significant ventricular arrhythmia requiring medication with antiarrhythmics or significant conduction system abnormality
- Serious concurrent infection or nonmalignant illness that is uncontrolled or whose control may be jeopardized by complications of study therapy
- Other malignancy within the past 3 years except non-melanomatous skin cancer or carcinoma in situ of the cervix
- History of or current brain metastases
- Psychiatric disorder that would preclude compliance
- Known dihydropyrimidine dehydrogenase deficiency
- Patients receiving a concomitant treatment with drugs interacting with S-1 or capecitabine such as flucytosine, phenytoin, warfarin, lamivudine, or allopurinol et al.
- Patients with known active infection with HIV, HBV, or HCV
- Major surgery within 4 weeks of start of study treatment, without complete recovery
- Radiotherapy within 4 weeks of start of study treatment; 2 weeks interval allowed if palliative radiotherapy was given to bone metastatic site and patient recovered from any acute toxicity
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: A
S-1 40mg/m2 orally twice daily on days 1 (evening) - 15 (morning)
|
S-1 40mg/m2 orally twice daily on days 1(evening) - 15 (morning)every 3 weeks, until disease progression, Capecitabine 1250mg/m2 orally twice daily on days 1 (evening) - 15 (morning)every 3 weeks, until disease progression
|
Active Comparator: B
Capecitabine 1250mg/m2 orally twice daily on days 1 (evening) - 15 (morning)
|
S-1 40mg/m2 orally twice daily on days 1(evening) - 15 (morning)every 3 weeks, until disease progression, Capecitabine 1250mg/m2 orally twice daily on days 1 (evening) - 15 (morning)every 3 weeks, until disease progression
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To evaluate each response rate of S-1 and capecitabine in the elderly and/or poor performance status patients with recurrent or metastatic gastric cancer
Time Frame: During Chemotherapy
|
During Chemotherapy
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
the duration of response, time to progression, progression-free survival,overall survival,the safety profiles,the quality of life,the CYP2A6 genetic polymorphism and its association with clinical outcomes in patients treated with S-1
Time Frame: During study period
|
During study period
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Sook Ryun Park, M.D, National Cancer Center, Korea
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NCCCTS-07-263
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stomach Neoplasms
-
Jeeyun LeeRecruitingStomach Cancer, AdenocarcinomaKorea, Republic of
-
Chinese University of Hong KongUnknown
-
Chinese University of Hong KongUnknown
-
National Cancer Center, KoreaUnknownSubmucosal Tumor of StomachKorea, Republic of
-
Xijing Hospital of Digestive DiseasesCompletedStomach Cancer | Esophageal Cancer | Esophageal Dysplasia | Stomach DysplasiaChina
-
Chinese University of Hong KongRecruiting
-
Universitätsklinikum Hamburg-EppendorfOvesco Endoscopy AGSuspendedSubmucosal Tumor of StomachGermany
-
Soonchunhyang University HospitalCompletedMalignant Neoplasm of Stomach | Benign Neoplasm of StomachKorea, Republic of
-
Fujian Cancer HospitalCompletedMalignant Neoplasm of Stomach Stage IVChina
-
Federation Francophone de Cancerologie DigestiveEli Lilly and CompanyActive, not recruitingStomach Cancer | Gastric Cancer | Gastroesophageal Junction Adenocarcinoma | Stomach NeoplasmFrance
Clinical Trials on S-1, capecitabine
-
Samsung Medical CenterNational Cancer Center, Korea; Asan Medical Center; Chonnam National University... and other collaboratorsCompletedColorectal CancerKorea, Republic of
-
The First Affiliated Hospital of Zhengzhou UniversityRecruiting
-
Seoul National University HospitalKorean Cancer Study Group; Ministry of Health & Welfare, KoreaCompletedChemotherapy Options for the First Line Chemotherapy in Elderly Patient With Advanced Gastric CancerGastric CancerKorea, Republic of
-
Peking UniversityTaiho Pharmaceutical Co., Ltd.Unknown
-
Hallym University Medical CenterSanofiCompletedColorectal NeoplasmKorea, Republic of
-
Japan Breast Cancer Research NetworkCompleted
-
Tomoshi TsuchiyaCompleted
-
Asan Medical CenterCompletedGastric CancerKorea, Republic of
-
Fudan UniversityThe First Affiliated Hospital of Anhui Medical University; Guangdong Provincial... and other collaboratorsWithdrawn
-
Peking University Cancer Hospital & InstituteRecruiting